Table of Contents Table of Contents
Previous Page  427 / 812 Next Page
Information
Show Menu
Previous Page 427 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S423

In this study we aimed to present and discuss six adolescents who

had received aripiprazole treatment aiming to reduce PRL levels

induced by various second generation antipsychotics.

Methods

Six patients were aged between 14 and 17 years. Five

of them were diagnosed as early onset schizophrenia and the

remaining one was diagnosed as bipolar 1 disorder. Risperidone,

amilsulpride, olanzapine and in some cases combinations of these

agents were responsible for hyperprolactinemia as displayed by

basal and fortnightlymeasurements of serumprolactin levels. Arip-

iprazolewere added to current antipsychotics and serumPRL levels

obtained every two weeks were recorded.

Results

Aripiprazole was used between 2.5–15mg’s initially and

reached up to 10–30mg per day within 3weeks. In all six cases

serum, PRL levels decreased by 9.1–88.76 percent.

Conclusions

Aripirazole seems to be promising in the treatment

of antipsychotic induced hyperprolactinemia in adolescents. Ran-

domized controlled studies necessitate.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1215

EV231

Psychiatrc symptoms induced by

montelukast: A case report

E. Aydın As¸ ık

1 ,

, S¸ . Yalın Sapmaz

2

1

Celal Bayar University Faculty of Medicine, Psychiatry, Manisa,

Turkey

2

Celal Bayar University Faculty of Medicine, Child and Adolescent

Psychiatry, Manisa, Turkey

Corresponding author.

Introduction

Montelukast is a leukotrienes receptor antagonist,

which is used, in chronic asthma, exercise induced broncocon-

striction and allergic rhinitis treatment. Montelukast inhibates the

proinflammatory cytokines and leukotriene is released from the

specific cells. Leukotrienes cause mucus secretion, vasodilatation,

broncoconstriction and eosinophilia. This case is about an asthma-

diagnosed child who had acute disturbing behaviour and sleeping

problems after using montelukast treatment.

Case

A 5 year-old boy assessed because of symptoms like

breaking the rules, disturbing friends, self-harming, hyperactivity,

distractability, insomnia and nightmares. In his history, when he

was 9months old acute hyperactivity, yelling, naughtiness, insom-

nia, disturbing and self-harming behaviours occurred suddenly

24 hours after intravenous montelukast treatment due to asthma

crisis. While he was still using oral montelukast, his parents had

cut off the treatment. After about 2months, there was decrease

in the symptoms. After using montelukast, these kinds of mis-

behaviour occurred again in a week. The montelukast treatment

was terminated controlled way under a pediatrician consultation.

Turgay DSM-IV Based Distruptive Behaviour Disorders Screening

and Rating Scale were completed by both of the parents in the

first interview and after 2months of cutting off montelukast treat-

ment. While comparing 2 scales and parents’ anamnesis, we found

that impulsivity, oppositional defiant, hyperactivity, distractability,

breaking off the rules, irritability, insomnia and having nightmares

reduced.

Conclusion

Montelukast can cause many psychiatric symptoms.

In that case we found sleeping problems and disturbing behaviour

caused or induced by montelukast treatment. As in that case, other

drugs also can cause or enhance psychiatric symptoms. So it is

important to assess the other drugs while assessing the diagnosis

and the treatment.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1216

EV232

Affective symptoms and emerging

psychotic disorder in adolescents

X. Benarous

Hôpital Pitié-Salpêtrière, Child and adolescent psychiatry

department, Paris, France

Depressive symptoms are frequently reported during the period

preceding the onset of schizophrenia in adolescents when such

symptoms can be mistaken for those of mood disorder. However,

it is unclear which emotional symptoms should be considered pre-

dictive of schizophrenia onset.

The types of emotional disturbances that may precede

schizophrenic disorder were sought through a review of historical

descriptive studies and seminal works using a phenomenological

approach. Five main types of emotional disturbances have been

found as prodromal symptoms of a schizophrenic disorder: (1)

increased sensitivity to stress, (2) poor or incomplete expres-

sion of emotions, (3) reduced emotion sharing, (4) emotional

detachment, and (5) disconnection between the perception and

expression of emotions. Studies based on phenomenological views

of schizophrenic disorders stressed the chronological sequence

of these symptoms in the same person. For example, the term

“delusional mood” (Wahnstimmung) coined to describe changes

in the perceived atmosphere encompass mood disturbances from

subtle emotional overreactivity to more severe symptoms that

could evoke athymhormia.

Analysis of recent studies among subjects at high-risk for psychotic

transition showed that the presence of mood symptoms at a very

early stage of the disorder is common. While these symptoms pre-

dict a lower level of general functioning, they were not associated

with a higher risk of developing a schizophrenic disorder at follow-

up.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1217

EV233

The RDoC roadmap to explore

neurocognitive difficulties of youths

with severely dysregulated mood:

Current findings and prospects

X. Benarous

Hôpital Pitié-Salpêtrière, Child and adolescent psychiatry

department, Paris, France

The Research Domain Criteria (RDoC) has been developed as

a multilevel approach to study neurocognitive impairments

in psychiatry. Considering the high prevalence and the func-

tional impairment associated with disruptive mood dysregulation

disorders (DMMD) in youths, a better understanding of the neurobi-

ological mechanisms underlying such emotional difficulties could

help guide therapeutics.

So far, three key difficulties in the socio-emotional neurocognitive

process have been documented in youths with DMDD:

– a deficit in the recognition of facial emotions has been found

(systems for social process/social communication construct). Func-

tional imagery has shown that such impairment is associated with

a hypoactivity of limbic neural structures, especially the amygdala.

Such findings are in line with those found in adults with depressive

episodes;

– poor flexibility during cognitive tasks (cognitive sys-

tems/cognitive effortful control construct). In particular, these

youths score poorly in neuropsychological tasks associated with

response reversal paradigm measuring the capacity to change

cognitive strategy when the rules of the game change implicitly.

These results partly explain the difficulties facing DMDD youths in

a frustrating context;